# A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer

> **NCT04254497** · — · COMPLETED · sponsor: **Changi General Hospital** · enrollment: 71 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** EGFR mutation detection kit

## Key facts

- **NCT ID:** NCT04254497
- **Lead sponsor:** Changi General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-11
- **Primary completion:** 2019-08-27
- **Final completion:** 2019-08-27
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254497, "A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04254497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*